Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production
LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs. Under the deal, Novo Holdings is purchasing…
#novonordisks #catalent #novo #novoholdings #novonordisk #bloomington #ind
